748P Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma
| Autor: | Oaknin, A., Drescher, C., Banda, K., Duska, L., Ribrag, V., Tewari, A., Lakhani, N.J., Eberst, L., Harvey, R.D., Sanchez, L.M. Manso, Lorusso, D., Kindler, H., Walter, H.S., Illescas, D.G., Pons-Tostivint, E., Thakur, A.G., Kann, L., Reddy, A., Faulhaber, N., González-Martín, A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S567-S568 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|